CT-95
Advanced Solid Tumors (e.g., Mesothelioma, Ovarian, Pancreatic)
Phase 1Active
Key Facts
Indication
Advanced Solid Tumors (e.g., Mesothelioma, Ovarian, Pancreatic)
Phase
Phase 1
Status
Active
Company
About Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company with a mission to transform cancer care by developing next-generation T cell engager (TCE) bispecific antibodies for solid tumors. The company has successfully pivoted and built a pipeline of three novel, clinical-stage TCE candidates, each featuring distinct engineering approaches to enhance efficacy and safety. Its strategy focuses on rapidly advancing these assets through early clinical trials to demonstrate proof-of-concept in difficult-to-treat cancers.
View full company profile